The amino acid sequence of the monovalent VHH construct BL3.1 and the bivalent VHH construct BL3.2, with the complementary-determining regions (CDRs) highlighted. The bivalent BL3.2 was created by gen
Complex of a camelid single-domain vhh antibody fragment with RNASE A at 2.5A resolution: SE5B-TRI crystal form with five se-met sites (L4M, M34, M51, F68M, M83) in vhh scaffold. Descriptor: ANTIBODY
Lower respiratory tract infections, such as infections caused by influenza A viruses, are a constant threat for public health. Antivirals are indispensable to control disease caused by epidemic as wel
Therapeutic blockade of the CD47/SIRPα axis by small molecules or monoclonal antibodies (mAbs) is a proven strategy to enhance macrophages-mediated anti-tumor activity. However, this strategy has been
